All Posts StratifiCare Unveils Promising Results of StratifiREY Radioembolization Effectiveness Prediction Test for Liver Cancer at SEA & ANZ Beckman Coulter User Group Meeting
StratifiCare is proud to announce the presentation of StratifiREY, our AI-powered blood test that predicts liver cancer patients’ response to yttrium-90 radioembolization (Y90-RE), at the recent SEA & ANZ CytoFLEX User Group Meeting hosted by Beckman Coulter Life Sciences.
Our R&D Scientist, Trinda Anne Ting, showcased our preliminary clinical results using Beckman Coulter’s DxFLEX clinical flow cytometer, demonstrating high predictive accuracy in identifying patients who will benefit from Y90-RE, an increasingly used internal radiation treatment for liver cancer.
